跳至主要内容
临床试验/NCT05343806
NCT05343806已完成不适用

Nifedipine Versus Magnesium Sulfate for Tocolysis in Pregnant Women at 32 - 36 Weeks Gestation With Threatened Preterm Labor

Assiut University2 个研究点 分布在 1 个国家目标入组 264 人开始时间: 2023年4月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
264
试验地点
2
主要终点
Number of women not delivered within 48 hours of starting tocolytic therapy.

研究概览

简要总结

Objective: This trial is designed to compare between the effectiveness of nifedipine versus magnesium sulfate (MgSO4) for tocolysis in women with threatened preterm labor.

Patient Population: The population will include pregnant women at gestational age between 32 and 36 weeks who are 18 years old or older and have signs of threatened preterm labor.

Study Design: This is a single-center, prospective, randomized controlled clinical trial. A total of 264 women pregnant between 32 and 36 weeks having threatened preterm labor will be enrolled and randomized into two parallel treatment arms. Patients in the group A will receive nifedipine, while patients in group B will MgSO4 only.

Treatment: All patients will be randomized on the day of enrollment. Patients with threatened preterm labor will receive the respective tocolysis in each group. All patients will receive corticosteroids for lung maturity according to the local protocol.

Primary outcome: Number of women not delivered within 48 hours of starting tocolytic therapy.

Secondary outcomes: perinatal mortality, a composite of adverse neonatal outcomes, birth weight, days on ventilation support, length of admission in neonatal intensive care, prolongation of pregnancy more than 7 days, delivery after 37 weeks of gestation, number of days till delivery, maternal mortality, maternal infection, and harm to mother from intervention.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women with threatened preterm labor defined as 3 or more uterine contractions in 30 minutes confirmed by cardiotocography.
  • Gestational age from 32 week + 0 days to (inclusive) 36 weeks + 0 days.
  • Women with singleton or multiple pregnancy.
  • Women with preterm prelabor rupture of membranes (PROM) will be included if they have uterine contractions.

排除标准

  • Contraindications for the use of either drugs, such as cardiac disease, hypotension, myasthenia gravis, or renal impairment.
  • Contraindications for tocolysis, such as intrauterine demise, intrauterine infection, fetal distress, placental separation, or severe pre-eclampsia.
  • Cervical dilatation > 5 cm.
  • Cervical length > 30 mm by trans-vaginal ultrasound.
  • Cervical cerclage.

研究组 & 干预措施

Nifedipine

Active Comparator

The initial dose of nifedipine will be 2 × 10 mg nifedipine capsules orally in the first hour, followed by 20 mg slow-release nifedipine every 6 hours for the next 47 hours. In the first hour after starting nifedipine, blood pressure and heart rate will be measured every 15 minutes. If blood pressure remains within the normal limits, treatment will be continued.

干预措施: Nifedipine 20 Mg (Drug)

Magnesium Sulfate

Active Comparator

Women will receive only MgSo4. A loading dose of MgSo4 will be given immediately after enrollment as 4 gm diluted in 200 mL of saline solution administered intravenous over a period of 20 minutes. Afterwards, the maintenance dose of MgSo4 will be administered intravenous in a dose of 1 gm/hour given as 6 gm diluted in 500 mL saline solution titrated with a rate of 100 mL per hour, then this dose is repeated every 6 hours for 48 hours. Respiratory rate and knee jerk will be assessed hourly for women in the MgSo4 group. Serum magnesium level will be measured if clinically indicated.

干预措施: Magnesium Sulfate (Drug)

结局指标

主要结局

Number of women not delivered within 48 hours of starting tocolytic therapy.

时间窗: 48 hours

postponing delivery for at least 48 hours to allow the time for corticosteroid administration for fatal lung maturity

次要结局

  • Delivery after 37 weeks of gestation(after 37th week of gestation)
  • Maternal infection rate(from starting treatment until 1 month after delivery)
  • days on ventilation support(within 1 month of delivery)
  • Perinatal mortality(From starting treatment until 1 month of delivery)
  • A composite of adverse neonatal outcomes(within 1 month of delivery)
  • length of admission in neonatal intensive care(within 1 month of delivery)
  • Maternal mortality rate(from starting treatment until 1 month after delivery)
  • Prolongation of pregnancy more than 7 days(7 days after initiation of therapy)
  • Number of days till delivery(from starting the intervention until delivery)
  • Harm to mother from interventions (side effects)(from starting treatment until 1 month after delivery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Karim Abdallah

Principal Investigator

Assiut University

研究点 (2)

Loading locations...

相似试验